Navigation Links
FASEB announces 2014 Science Research Conference: Lipid and Lipid Regulated Kinases in Cancer
Date:1/22/2014

Bethesda, MD This 2014 FASEB Science Research Conference focuses on recent advances in our understanding of lipid-regulated signal transduction cascades, lipid mediators, and lipid targets that are known to play major roles in the initiation and progression of human cancers.

This FASEB Conference brings together physician-scientists, basic scientists and scientists from industry for presentations, discussion, and collaboration to broaden our understanding of how these pathways drive cancer, and to explore these and the associated signaling network as targets for cancer therapy. There are numerous challenges in this relatively young, yet rapidly evolving field. Perhaps most critical is understanding the molecular mechanisms by which lipid effectors modulate mitogenesis, cell cycle regulation, cell death and differentiation in transformed cells, and elucidating how intracellular generation of bioactive lipids is altered in transformed cells and contributes to cancer progression.

This meeting strives to provide researchers with an update on current basic, mechanistic discoveries, and to place these discoveries in the proper translational and clinical context. Meeting topics include: The phosphoinostide pathway and its effectors including the protein kinase C (PKC) isozymes, Rho family GTPases, and Ras; modification of membrane phosphoinostides by PI3K, activation of the Akt isozymes and their downstream targets such as mTOR; new phospholipases and the characterization of novel effectors of bioactive products such as COX2 and the isoprostanes; and lipid post-translational modifications of the Ras oncogene and other GTPases that contribute to their transforming activities.


'/>"/>

Contact: Robin Crawford
src@faseb.org
301-634-7010
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. FASEB announces 2014 Science Research Conference: Folic Acid, Vitamin B12 and One Carbon Metabolism
2. FASEB announces 2014 SRC: Phospholipid Cell Signaling & Metabolism in Inflammation & Cancer
3. FASEB announces 2014 Science Research Conference: Molecular Biophysics of Membranes
4. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
5. FASEB announces 2014 Science Research Conference: Nutrient Sensing and Metabolic Signaling
6. FASEB announces 2014 Science Research Conference: Retinal Neurobiology and Visual Processing
7. FASEB announces 2014 Science Research Conference: Virus Structure and Assembly
8. FASEB announces 2014 Science Research Conference: Protein Folding in the Cell
9. FASEB announces 2014 Science Research Conference: 2nd International Conference on Retinoids
10. FASEB announces SRC: Molecular Mechanisms of Intestinal Lipid Transport & Metabolism
11. FASEB announces 2014 SRC: Protein Phosphorylation, Cellular Plasticity & Signaling Rewiring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology: